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3ABSTRACT 
Background 
Soft tissue sarcomas are heterogeneous and a major complication in 
their management is that the existing classification scheme is not definitive 
and is still evolving.  Leiomyosarcomas, a major histologic category of soft 
tissue sarcomas, are malignant tumours displaying smooth muscle 
differentiation.  Although defined as a single group, they exhibit a wide range 
of clinical behaviour.  We aimed to carry out molecular classification to identify 
new molecular subgroups with clinical relevance. 
Methods 
We used gene expression profiling on twenty extra-uterine 
leiomyosarcomas and cross-study analyses for molecular classification of 
leiomyosarcomas.  Clinical significance of the subgroupings was investigated.  
Results 
We have identified two distinct molecular subgroups of 
leiomyosarcomas.  One group was characterised by high expression of 26 
genes which included many genes from the sub-classification gene cluster 
proposed by Nielsen et al.  These sub-classification genes include genes that 
have importance structurally as well as in cell signalling.  Notably, we found a 
statistically significant association of the subgroupings with tumour grade. 
Further refinement led to a group of 15 genes that could recapitulate the 
tumour subgroupings in our dataset and in a second independent sarcoma 
set.  Remarkably, cross-study analyses suggested that these molecular 
subgroups could be found in four independent datasets, providing strong 
support for their existence. 
4Conclusions  
Our study strongly supported the existence of distinct leiomyosarcoma 
molecular subgroups, which have clinical association with tumour grade.  Our 
findings will aid in advancing the classification of leiomyosarcomas and lead 
to more individualised and better management of the disease. 
5INTRODUCTION 
Adult soft tissue sarcomas are malignant tumours that occur in 
connective tissues throughout the body, other than the bone or cartilage 
(Goldblum et al, 2014). Major histologic categories of soft tissue sarcomas 
include leiomyosarcoma (smooth muscle differentiation), liposarcoma (fatty 
differentiation), rhabdomyosarcoma (striated muscle differentiation), synovial 
sarcoma and undifferentiated pleomorphic sarcoma.  These tumours are 
heterogeneous and a major complication in the management of this disease is 
that the existing classification scheme is not definitive and is still evolving. 
Leiomyosarcomas are malignant tumours with smooth muscle differentiation 
that are defined as a single group based on morphology and 
immunohistochemical examination, while exhibiting a wide range of clinical 
behaviour that correlates to some extent with histological grade (Goldblum et 
al, 2014).  Gastrointestinal stromal tumour (GIST) was historically classified 
as gastrointestinal leiomyosarcoma prior to the identification of activating 
mutations in KIT by Hirota et al. (1998) and the immunohistochemical 
association with interstitial cells of Cajal by Kindblom and others (Kindblom et 
al, 1998) in the late 1990’s.  Advances in molecular understanding and 
techniques clearly distinguished GIST from leiomyosarcoma, and with the 
advent of imatinib therapy this became a paradigm for the molecularly 
targeted treatment of cancer (Bauer & Joensuu, 2015; Nishida et al, 2015; 
Verweij et al, 2004).  This clearly illustrates the importance of improving the 
classification of sarcomas and the beneficial effect this can have on disease 
management and patient outcome.  With further advances in modern 
molecular techniques, it is hoped that we would be able to better molecularly 
6classify the tumours into subgroups, which may eventually lead to improved 
management of the disease.  To this end, we have used microarray gene 
expression profiling to study the expression pattern of leiomyosarcomas with 
the aim of improving its molecular classification and identifying new molecular 
subgroups that may be of clinical relevance.  We have focused on 
leiomyosarcomas of extra-uterine origin in this study as uterine 
leiomyosarcoma represents a relatively distinct clinical entity and can be 
easily identified from its site of origin (Amant et al, 2009; Linch et al, 2014). 
Our findings provide important support to the initial findings of Nielsen et al. 
(2002) in an independent sarcoma set.    
Nielsen et al. (2002) used microarrays to molecularly characterise 41 
soft tissue tumours which included some leiomyosarcomas and GISTs as well 
as tumours of other histologic categories.  They noted a distinct gene 
expression pattern of the GISTs that was distinct from the leiomyosarcomas. 
11 leiomyosarcomas were included in their study, and they found initial 
evidence of separation of leiomyosarcomas into two subgroups, one group 
characterised by the high expression of a group of 24 gene representing 20 
distinct genes which included the gene for calponin and other genes 
implicated in muscle structure and function.  Recently, coinciding with our 
investigations, other studies also suggested the existence of subtypes of 
leiomyosarcoma (Beck et al, 2010; Guo et al, 2015).  In this study we further 
investigated the molecular classification of leiomyosarcomas and the clinical 
relevance of the new classification.   
MATERIALS AND METHODS 
7Microarray procedures 
Leiomyosarcoma is a relatively rare form of cancer.  Sarcoma tissue 
samples used in this study were collected from patients undergoing surgery at 
two hospitals (the Royal Marsden NHS Foundation Trust, London and the 
Royal Orthopaedic Hospital NHS Foundation Trust, Birmingham) that treat 
significant numbers of sarcoma patients in the UK over the period of 1987 to 
2001.  Diagnoses were performed by experienced sarcoma pathologists using 
conventional criteria, including immunohistochemistry and electron 
microscopy, if appropriate.  This study was conducted with the approval of our 
local Research Ethics Committee.  Clinicopathologic descriptions of the cases 
are shown in Supplementary Table S2.  (Summary patient characteristics: 
median age = 61 years; sex (M = 58%, F = 42%); location (extremity = 58%, 
non-extremity (thoracic/abdominal/retroperitoneal sites) = 42%); tumour size 
(5 cm or less in greatest dimension = 21%, more than 5 cm in greatest 
dimension = 79%).)  The tumour samples were snap-frozen in liquid nitrogen 
and stored at –80ºC until RNA extraction.  Tumour and control RNA 
preparation were performed as in Lee et al. (2003), except that HB4a was not 
included in the control RNA.  Microarray slides were gridded with 11622 spots 
consisting of 1937 I.M.A.G.E cDNA clones (gridded six times each) acquired 
from the UK Human Genome Mapping Project Resource Centre and 
Research Genetics (http://www.resgen.com).  The majority of the clones 
included were selected at random, except for the 23 gene probes that 
corresponded to 18 of the distinct genes reported by Nielsen et al. (2002) as 
described below.  We were unable to get hold of the clones that corresponded 
to the other two of the 20 distinct genes that distinguished their 
8leiomyosarcoma samples into the two subgroups.  Information on the geneset 
can be found at the supplementary information online (Supplementary Table 
S1) (Array data to be found on Gene Expression Omnibus  GSE76216).  The 
preparation of the microarray slides including gridding and blocking were as 
described in Clark et al. (Clark et al, 2002), except that the BioRobotics 
Microgrid II was used for gridding in this study.  RNA labelling was performed 
as in Lee et al. (2003), except that after the final wash with 400 μl 0.5x SSPE, 
the sample was reduced to a volume of 4 μl.   
Microarray hybridisation was performed as in Lee et al. (2003) except 
the following: after the coverslip fell off, the slide was then washed with 4x 
SSPE, 10 mM EDTA for 1 min at 42oC; then 50% formamide, 6x SSPE at 
42oC for 15 sec with gentle rocking; then 2x SSPE, 10mM EDTA for 30 sec at 
room temperature; and 0.1x SSPE for 30 sec at room temperature.  The slide 
was then rinsed briefly with HPLC grade water and dried with canned air. 
Hybridised microarray slides were scanned in a GenePix 4000B 
scanner (Axon Instruments, Foster City, CA) as described before (Lee et al, 
2004) and slides were scanned at PMT (photomultiplier tube) voltage levels 
that provided a Cy5:Cy3 hybridisation ratio across the slide of roughly 1.   
Analysis of microarray data 
Data processing and analyses were performed with the GenePix Pro 
software (Axon Instruments, Foster City, CA) and the GeneSpring software 
(Silicon Genetics, Redwood City, CA).  Background determination and 
flagging were performed as described before (Lee et al, 2004).  Further 
quality filtering was performed by excluding spots with fluorescent spot 
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intensity in the control channel being less than 1.4 times the local background 
of that channel.  Ratios of fluorescent intensities (Cy5:Cy3) for individual 
cDNA were then determined after subtraction of background as described 
before (Lee et al, 2004) except that the average fluorescent intensity ratios of 
replicate spots were used.  These ratios were then normalised by making the 
median of all measurements in each sample to be 1.  The resulting ratios 
were further normalised so that the median of all measurements taken for a 
particular gene is 1.  To obtain genes that showed variation in expression 
among the tumours, a subset of genes that had normalised expression ratios 
of above 2 in at least 5 of the samples or below 0.5 in at least 5 of the 
samples were selected.  Hierarchical clustering was then applied to the log-
transformed data for these genes and the tumours, using average-linkage 
clustering with Pearson correlation around zero as the similarity metric.  Only 
genes with expression data present in half or more of the tumour samples 
following quality filtering were included in the gene clustering.  Clustering 
analysis was also performed with the ‘leio-subclass’ genes from Nielsen et al. 
(2002) present in our array, as well as gene clusters identified from our 
dataset.  Class comparison analysis (BRB array tools) using two sample t test 
and multivariate permutations test computed based on 1000 random 
permutations (confidence level of false discovery rate assessment: 80 %; 
maximum allowed proportion of false-positive genes: 0.1) was carried out to 
identify statistically significant genes associated with the group I and II 
tumours.    
Gene expression data of the 17 leiomyosarcomas reported in the study 
by Baird et al. (2005) were downloaded from Gene Expression Omnibus 
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(GEO) data repository.  Array data normalisation and clustering analysis were 
performed as described above. 
Other statistical analyses including Kendall’s taub for assessing the 
significance of association between tumour subgroupings and tumour grade 
were performed using SPSS (SPSS Inc, Chicago, IL).   
 
RESULTS 
The expression profiles for 20 leiomyosarcomas were investigated 
using cDNA microarrays.  To better explore the expression differences that 
may exist between the different tumours, a subset of 169 genes that showed 
the most variation in expression among the tumours was used in the cluster 
analysis.  Hierarchical clustering using these most varied genes in this set of 
tumours gave rise to two clusters of tumours (Fig. 1), one group (group I) was 
characterised by higher expression of a cluster of 26 genes.  Ten of these 
genes were also found in the 20 distinct genes reported by Nielsen et al. 
(2002).  In making this array, we have mined the expression data from 
Nielsen et al. (2002) and have specifically included clones that corresponded 
to all except 2 of the 20 distinct genes from Nielsen et al. (2002) (‘leio-
subclass’ genes) that distinguished their leiomyosarcoma samples into the 
two subgroups that they called the ‘Calponin’ subgroups (Supplementary 
Table S1).  This allowed us to specifically carry out clustering analysis using 
the expression of these ‘leio-subclass’ genes (23 gene probes corresponding 
to 18 of the distinct genes reported by Nielsen et al. (2002)).  Hierarchical 
clustering analysis on the tumours using these 23 ‘leio-subclass’ genes 
representing 18 distinct genes gave rise to 2 groups of tumours, with one 
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group of tumours exhibiting high level of expression of these  genes (called 
‘Calponin-positive’ group by Nielsen et al. (2002)) (Fig. 2).   Gene clustering 
was also carried out for the 12 of these genes that satisfied the criteria for use 
in gene clustering (Fig. 2). 
We repeated tumour clustering analysis using only the cluster of 26 
genes that defined the groupings in the ‘most varied genes’ analysis (Fig. 3), 
and the result showed two distinct clusters of tumours, with a well-defined 
cluster of 8 tumours (group I) that matched exactly with the tumours identified 
to be ‘Calponin-positive’ using the ‘leio-subclass’ genes. 
The group I tumours were defined by the high expression of this cluster 
of 26 genes (Table 1).  We noted that 10 of the ‘leio-subclass’ genes were 
present in the most varied genes (169 genes), and remarkably, all 10 of these 
10 ‘leio-subclass’ genes were found in this cluster of 26 genes.  The 16 
additional genes that were new to the ‘leio-subclass’ gene cluster were also 
shown in Table 1, and included a number of genes that have structural 
importance for plasma membrane (EVI2B), basement membrane (COL4A2; 
COL4A1; NID1) and in extracellular matrix (MFAP4); cell adhesion (CDH1; 
ITGA1); as well as genes that have important functions like cell signalling 
(JAG1 involved in Notch signalling; GNAZ in transmembrane signalling; 
PTCH1 in hedgehog and other signalling).      
We then looked into the clinical relevance of these subgroups of 
tumours.  Analysis of relevant clinical data showed a statistically significant 
association of the subgroupings with tumour grade (Kendall’s taub 0.650, 
P<0.01) (Table 2).  Group I was found to be associated with lower tumour 
grade.  We have not found any statistically significant association of the 
12
cluster grouping with other clinical parameters (tumour size (≤5 cm or >5cm), 
site (superficial or deep), location (extremity or non-extremity), stage (I to IV) 
or tumour status (primary, local recurrence or metastasis)) (Supplementary 
Table S2). 
We noted that a cluster of 15 genes were best associated with the 
subgroupings of tumours and may allow us to further refine the genelist, so 
these were tested to see if they could recapitulate the subgroupings of 
tumours (Table 1).  We performed clustering analysis with this group of 15 
genes and found that the tumours were clustered in the same two groups as 
with the use of the larger gene clusters; one group was defined by the high 
expression of these genes (Supplementary Fig. S1).  We further validated the 
use of this group of 15 genes in an independent sarcoma set that has not 
been used for identifying subgroups.  We downloaded and analysed the gene 
expression data of the 17 leiomyosarcomas in the sarcoma study by Baird et 
al. (2005).  13 of the genes in their dataset were mapped to genes found in 
our group of 15 genes and clustering analysis was performed accordingly. 
We found that these genes also defined a subgroup of tumours (ten) that had 
high expression of these genes. 
There was also interest in identifying potential targets for therapy 
associated with the two subgroups, particularly as they were found to be 
clinically relevant.  Class comparison analysis using two sample t test and 
multivariate permutations test was performed to identify statistically significant 
genes associated with our two subgroups.  The statistically significant genes 
were compared with the genes from the TARGET V3 database (Allen et al, 
2014) that contains over 130 genes at present which are believed to have 
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therapeutic, prognostic, and diagnostic implications for cancer patients, and 
are of particular interest in translational oncology.  Our comparison showed 
that two of the genes (CDH1 and PDGFRA) in our gene list are found in these 
TARGET genes and may be potential subgroup-specific targets.  The high 
expression of CDH1 is associated with group I tumours.  This gene has been 
reported to be of diagnostic value and is frequently mutated in lobular breast 
carcinoma and in certain hereditary cancer syndromes, including a type of 
gastric cancer (Allen et al, 2014).  The high expression of PDGFRA is 
associated with group II tumours, and is associated with sensitivity to tyrosine 
kinase inhibitors (Allen et al, 2014).    
     
DISCUSSION       
Gene expression profiling has become an increasingly important aid in 
the molecular diagnosis and classification of human malignancies, including 
soft tissue sarcomas (Alizadeh et al, 2000; Bittner et al, 2000; Elias et al, 
2015; Francis et al, 2007; Golub et al, 1999; Lee et al, 2003; Nielsen et al, 
2002; Perou et al, 2000; Tschoep et al, 2007).  Although the existing 
classification permits soft tissue tumours to be distinguished from one 
another, there is still much room for improvement in the classification scheme.  
Identification of new molecular subtypes will aid in the management of the 
disease, which was well illustrated by the introduction of the diagnostic 
category GIST and the development of new targeted therapies specific to this 
class of tumours which have revolutionised its treatment (Nishida et al, 2015).  
In this study, we have attempted to identify molecular subtypes of 
leiomyosarcoma using an array designed to allow one to further investigate 
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the subgroupings proposed by Nielsen et al. (2002).  We have focused on 
leiomyosarcomas of extra-uterine origins as uterine leiomyosarcoma 
represents a relatively distinct clinical entity and can be easily identified from 
its site of origin (Amant et al, 2009; Linch et al, 2014).  When clustering 
analysis was performed in our tumour set using the ‘leio-subclass’ genes 
reported by Nielsen et al. (2002), we similarly found two subgroups of 
leiomyosarcomas.  Additionally, tumour clustering using a set of most varied 
genes (169 genes) in our dataset also gave rise to two groups of tumours that 
very much matched the tumour groupings using the 18 ‘leio-subclass’ gene 
set.  These groups of tumours were defined by the high expression of a 
cluster of 26 genes (Table 1).  16 additional genes were new to the ‘leio-
subclass’ gene cluster and it is interesting to note that a number of these 
genes have structural importance just like genes reported in Nielsen et al. 
(2002) being implicated in muscle structure and function which included 
Calponin, laminin, actin, and leiomodin.  Also included in these 16 additional 
genes was the gene for D10S170 DNA fragment (clone 563392, now called 
CCDC6 coiled-coil domain containing 6), which was present immediately next 
to the ‘leio-subclass’ genes in the gene dendrogram from Nielsen et al. (2002) 
and also showed similar expression pattern to these genes.  Though its gene 
function is still largely unknown, it has been suggested to have tumour 
suppressor function.  It is worth noting that COL4A1 and COL4A2 are two 
closely related genes located on the same chromosome.  COL4A2 gene is 
organised in a head-to-head conformation with the other type IV collagen 
gene COL4A1 so that the gene pair shares a common promoter.  This 
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supported the reliability of the microarray data as both genes were picked up 
and were clustered next to each other in clustering analysis. 
The tumour groupings using the most varied genes largely matched 
with the groupings using the ‘leio-subclass’ genes, but there was a small 
difference in the groupings that could have arisen from the noise in the data. 
We might have included many genes in the clustering using the most varied 
genes that are not relevant to the ‘Calponin’ groupings.  So clustering analysis 
was performed using the cluster of 26 genes that defined the tumour 
subgroups, and we obtained two groups that matched exactly with the two 
groups from clustering using the ‘leio-subclass’ genes.      
Nielsen et al. (2002) reported that too few cases were available to 
allow for meaningful comparison based on histological findings between the 
two groups.  And within the limit of their study, clinical features, such as 
tumour location, did not account for the separation of the leiomyosarcomas 
into the two subgroups.  They did not comment directly on other clinical 
associations apart from tumour location.  We have investigated possible 
association with various clinical parameters, and we have found a statistically 
significant association of the subgrouping of leiomyosarcomas with tumour 
grade.  The histological grading of soft tissue sarcomas is determined by an 
assessment of various factors including differentiation (pleomorphism of 
tumour cells), mitotic activity, degree of cellularity, matrix formation, and 
amount of necrosis (Oliveira & Nascimento, 2001; Trojani et al, 1984).  It is 
considered an important prognostic factor for adult soft tissue sarcomas and 
has been used in guiding patient management (Oliveira & Nascimento, 2001). 
However, a consistent reproducible grading system can at times be difficult to 
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achieve (Oliveira & Nascimento, 2001). Genes identified from these gene 
expression studies may aid in achieving better tumour grading, and may be 
particularly useful in difficult cases. 
We have further refined the genelist to a group of 15 genes that could 
recapitulate the tumour subgroupings in our dataset, and have validated this 
genelist in an independent sarcoma set from Baird et al. (2005) where we also 
found a subgroup of tumours defined by this group of genes.  Unfortunately, 
associated clinical data were not available and one could not assess the 
association of tumour subgrouping with tumour grade in this dataset.  
Guo et al. have recently used gene expression profiling to identify three 
molecular subtypes of leiomyosarcoma using formalin-fixed, paraffin-
embedded tumour samples (Guo et al, 2015) following their earlier study 
(Beck et al, 2010): subtype I was the subgroup that was relatively well defined 
molecularly and had higher expression of genes enriched for processes that 
included muscle contraction, muscle system processes, and cytoskeleton 
organisation.  Subtype II had less muscle-specific gene expression than 
subtype I.  Guo et al. have proposed the use of LMOD1 (replacing CASQ2 
proposed in their earlier study) together with the proteins ACTG2, SLMAP, 
MYLK, CFL2 to be the panel of subtype I immunohistochemical biomarkers.  
They have also proposed the use of ARL4C to be the subtype II biomarker.  
They have not proposed any immunohistochemical markers for subtype III.  
Subtype III appeared to be less well-defined molecularly and when they 
attempted to investigate if they could find these three subtypes in another 
publicly available gene expression dataset, they noted that their subtypes I 
and II could be significantly reproduced in this dataset, but not subtype III.  
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However, they noted from related clinical information that clinically subtype III 
tumours were mostly of uterine origin (92% in their own tumour set) and 
uterine leiomysarcoma was significantly associated with subtype III.  In our 
study, we have found two distinct molecular subgroups of leiomyosarcomas. 
As we did not include tumours of uterine origin in our study, it is expected that 
we would not find a subgroup that corresponded to their subtype III.  Our 
group I was defined by a cluster of 26 genes (Table 1) which included many 
genes implicated in muscle structure and function.  We noted that LMOD1 
and ACTG2 from the panel of 5 genes whose encoded proteins they 
proposed to be used as immunohistochemical markers for subtype I were also 
found in our 26 group I defining genelist.  In fact, further investigation showed 
that the majority of the genes in our group I defining genelist were ranked 
highly in their list of genes that had a higher expression in subtype I versus 
other subtypes including LMOD1, MYL9, MYH11, ACTA2, ACTG2, CNN1, 
ALDH1B1, COL4A2, COL4A1, CRYAB, CYFIP2, MFAP4, CDH1, JAG1, 
DSTN and GNAZ.  They have proposed the use of ARL4C as 
immunohistochemical marker for subtype II, but this gene was not included in 
our array.  On the other hand, a cluster of 4 genes that correlated with and 
had higher expression in our group II (GJA1, COL5A2, THBS2, MFAP2) were 
also found to be highly ranked in their list of significant genes that had a 
higher expression in subtype II versus other subtypes.  In fact, the first three 
of these genes were ranked higher (more significantly associated with 
subtype II) than the ARL4C whose protein they had chosen to be the 
immunohistochemical marker for subtype II in their study.  It is perhaps worth 
noting that the use of a single protein ARL4C to be subtype II marker and its 
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use in classifying tumours as subtype II or not using immunohistochemistry 
had quite a significant error rate (31% of their tumour samples were 
misclassified into a different subtype than the original classification based on 
gene expression profiles), so perhaps a combination of markers would help to 
improve the accuracy of an immunohistochemical classification.  Class 
comparison analysis was also performed to identify statistically significant 
genes associated with our two subgroups, we got similar genes to the clusters 
of group-defining genes mentioned above that also corresponded to their 
significant genes for subtype I and II respectively.  On the whole, our findings 
suggested that our group I corresponded to their subtype I; and our group II 
corresponded to their subtype II; providing further support to the existence of 
these two molecular subgroups (in a UK dataset).  Though they have found 
that low-grade tumours were more frequent in their subtype I, this did not 
reach statistical significance in their dataset; whereas in our dataset, we have 
found a statistically significant association of the subgroups with tumour 
grade, with group I being associated with lower grade.              
Chibon et al (2010) has reported on identifying a gene expression 
signature, which they have called CINSARC – Complexity INdex in 
SARComa, that was found to be associated with metastatic outcome in a 
mixture of different soft tissue sarcomas.  The CINSARC gene set is 
composed of 67 genes related to mitosis and chromosomal stability.  We have 
compared the CINSARC genes with the statistically significant genes 
associated with our two subgroups and found no overlap in these genes.  It is 
perhaps not too surprising as although the authors found that the CINSARC 
genes could predict metastatic behaviour in soft tissue sarcomas in general, 
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the authors had also done a survival analysis in their validation set of 
leiomysarcomas and reported that they could not find a statistically significant 
difference in metastasis-free survival in their two subgroups (Chibon et al, 
2010).  
To conclude, we have identified two molecular subgroups of 
leiomyosarcomas, one group being characterised by the high level of 
expression of a cluster of 26 genes that included many genes in the ‘leio-
subclass’ genes, and provided confirmation of the findings of Nielsen et al. 
(2002) in an independent sarcoma set.  We have also identified additional 
genes to the original ‘leio-subclass’ gene cluster that contributed to sub-
classification of leiomyosarcoma.  We have also investigated the clinical 
significance of the groupings and found an association with tumour grade.  
We have further refined our genelist to a group of 15 genes that could 
recapitulate the tumour subgroupings in our dataset, and have validated this 
in an independent sarcoma set from Baird et al. (2005).  Further comparison 
with a recently published dataset suggested that our findings also matched 
with two molecular subgroups in their dataset (Guo et al, 2015).  Cross-study 
comparisons and analyses of expression datasets were renowned for often 
giving rise to discrepant or completely different results.  Quite remarkably, our 
findings suggested that the two distinct molecular subgroups identified here 
could be found across four independent datasets, providing strong support for 
their existence.  Our findings will aid in achieving a better classification of 
leiomyosarcomas and eventually lead to better management of the disease 
and more individualised therapies for sarcoma patients. 
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Figure legends 
Fig. 1 Two-dimensional cluster analysis of leiomyosarcomas (horizontal) and 
most varied genes (vertical).  Each column corresponds to a tumour, and 
each row corresponds to a gene.  Red indicates overexpression, while green 
indicates underexpression.  Grey indicates missing or excluded data.  Asterisk 
indicates the tumour belongs to group I in clustering analysis of fig. 2. 
Fig. 2 Hierarchical clustering analyses of leiomyosarcomas (vertical) and the 
‘leio-subclass’ genes in our array (horizontal).  Each row corresponds to a 
tumour, and each column corresponds to a gene.  Red indicates 
overexpression, while green indicates underexpression.  Grey indicates 
missing or excluded data.  Asterisk indicates the tumour belongs to group I in 
this clustering analysis. 
Fig. 3 Hierarchical clustering analyses of leiomyosarcomas (vertical) and the 
26 genes (horizontal).  Each row corresponds to a tumour, and each column 
corresponds to a gene.  Red indicates overexpression, while green indicates 
underexpression.  Grey indicates missing or excluded data.  Asterisk indicates 
the tumour belongs to group I in clustering analysis of fig. 2. 



Table 1 List of genes in the cluster of 26 genes that defined the leiomyosarcoma 
subgrouping 
 
Spot ID I.M.A.G.E. 
Clone ID 
UniGene 
Cluster 
Symbol Name 
774078 774078 Hs.519075 LMOD1 Leiomodin 1 (smooth muscle) 
1473274 1473274 Hs.504687 MYL9 Elongation factor Tu family protein 
502177 502177 Hs.460109 MYH11 Myosin, heavy polypeptide 11, smooth muscle 
212621 212621 Hs.500483 ACTA2 Actin, alpha 2, smooth muscle, aorta 
81289 81289 Hs.516105 ACTG2 Actin, gamma 2, smooth muscle, enteric 
726779 726779 Hs.465929 CNN1 Calponin 1, basic, smooth muscle 
197657 197657 Hs.436219 ALDH1B1 Aldehyde dehydrogenase 1 family, member B1 
28218 28218 Hs.7195 GABRG2 Gamma-aminobutyric acid (GABA) A receptor, gamma 2
769959 769959 b Hs.508716 COL4A2 Collagen, type IV, alpha 2 
491692 491692 b Hs.17441 COL4A1 Collagen, type IV, alpha 1 
1677204 1677204 b Hs.356624 NID Nidogen 1 
362059 362059 Hs.436367 LAMA3 Laminin, alpha 3 
785744 a 785744 b Hs.494538 PTCH Patched homolog (Drosophila) 
839736 839736 b Hs.53454 CRYAB Crystallin, alpha B 
868304 868304 Hs.500483 ACTA2 Actin, alpha 2, smooth muscle, aorta 
593183 593183 b Hs.5509 EVI2B Ecotropic viral integration site 2B 
47475 47475 b Hs.519702 CYFIP2 Cytoplasmic FMR1 interacting protein 2 
759173 a 759173 b Hs.296049 MFAP4 Microfibrillar-associated protein 4 
251019 251019 b Hs.461086 CDH1 Cadherin 1, type 1, E-cadherin (epithelial) 
121316 a 121316 b Hs.224012 JAG1 Jagged 1 (Alagille syndrome) 
563392 563392 b Hs.591360 CCDC6 Coiled-coil domain containing 6 
212078 a 212078 b Hs.644352 ITGA1 integrin, alpha 1 
768292 a 768292 b Hs.304192 DSTN Destrin (actin depolymerizing factor) 
741880 741880 b Hs.557097 PBX1 Pre-B-cell leukemia transcription factor 1 
40773 40773 b Hs.584760 GNAZ Guanine nucleotide binding protein (G protein), alpha z 
polypeptide 
161484 a 161484 b - - Multiple genes 
 
a Clones that were found by DNA sequencing to have a sequence different from the one originally 
associated with the I.M.A.G.E. clone ID during sequence confirmation of the genes. 
b Genes that were new to the ‘leio-subclass’ genes. 
 
NB: The refined group of 15 genes were shown as the top 15 genes in this table.  
 
 
Table 2 
Distribution of tumour grade versus tumour subgroup 
Tumour subgroup Total
Group I Group II 
Tumour 
grade 
1 1 0 1
2 5 1 6
3 2 9 11
Total 8 10 18
